This report describes the global market size of Neuromodulation from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 29.5% from 2024 to 2031.
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Neuromodulation estimated at US $3.25Billion in the year 2022, is projected to reach a revised size of US $ 1,374.15 Billion by 2031, growing at a CAGR of 29.5% during the forecast period 2024-2031.
Neuromodulation refers to the process of altering nerve activity through targeted delivery of electrical, chemical, or mechanical stimuli to specific areas of the nervous system. This technique aims to modify neural function and influence the way the brain and spinal cord process information, thereby affecting various physiological and psychological functions. Neuromodulation can be applied through various methods, including electrical stimulation (e.g., deep brain stimulation, spinal cord stimulation), pharmacological interventions, and other techniques such as transcranial magnetic stimulation (TMS). It is used to treat a wide range of conditions, including chronic pain, movement disorders (e.g., Parkinson's disease), depression, and epilepsy. By adjusting the activity of neural circuits, neuromodulation offers therapeutic potential for managing symptoms and improving quality of life for patients with neurological and psychiatric disorders.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Neuromodulation as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Technology
Electrical Neuromodulation
Deep Brain Stimulation (DBS)
Spinal Cord Stimulation (SCS)
Transcranial Magnetic Stimulation (TMS)
Vagus Nerve Stimulation (VNS)
Chemical Neuromodulation
Intrathecal Drug Delivery Systems (IDDS)
Gene Therapy
Magnetic Neuromodulation
Magnetic Resonance Imaging (MRI) Guided Neuromodulation
Repetitive Transcranial Magnetic Stimulation (rTMS)
Neuromodulation technologies encompass various techniques to modify nerve activity and manage neurological conditions. Electrical neuromodulation includes methods such as Deep Brain Stimulation (DBS), which involves implanting electrodes in the brain to regulate abnormal neural activity, often used for Parkinson's disease. Spinal Cord Stimulation (SCS) involves implanting a device that sends electrical impulses to the spinal cord to alleviate chronic pain. Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain, providing treatment for depression and other conditions. Vagus Nerve Stimulation (VNS) involves implanting a device that stimulates the vagus nerve to influence brain activity, used for epilepsy and depression. Chemical neuromodulation includes Intrathecal Drug Delivery Systems (IDDS), which deliver medication directly to the spinal fluid to manage pain and spasticity, and Gene Therapy, which involves altering genetic material to correct neural dysfunction. Magnetic neuromodulation techniques include Magnetic Resonance Imaging (MRI) Guided Neuromodulation, which combines MRI imaging with neuromodulation techniques to target specific brain regions accurately, and Repetitive Transcranial Magnetic Stimulation (rTMS), which repeatedly applies magnetic pulses to the brain to treat mental health disorders like depression. Each of these technologies aims to adjust neural activity to improve patient outcomes for various neurological and psychiatric conditions.
By Application
Pain Management
Neurodegenerative Disorders
Epilepsy
Depression and Mental Health
Others
The Global Neuromodulation is segmented by application into Pain Management, Neurodegenerative Disorders, Epilepsy, Depression and Mental Health, and Others. Pain Management involves using neuromodulation techniques to alleviate chronic pain conditions, providing an alternative to traditional pain medications. In Neurodegenerative Disorders, neuromodulation helps manage symptoms of diseases like Parkinsons and Alzheimers, improving patient quality of life. For Epilepsy, devices like Vagus Nerve Stimulation (VNS) reduce seizure frequency in patients who do not respond to medication. Neuromodulation is also used in treating Depression and Mental Health conditions, such as with Transcranial Magnetic Stimulation (TMS), whichprovides relief for treatment-resistant depression. Other applications include managing conditions like migraines, tinnitus, and incontinence. These diverse
applications highlight the versatility and therapeutic potential of neuromodulation technologies in addressing a wide range of medical conditions.
By Patient Demographics
Adults
Pediatric
Geriatric
The Global Neuromodulation is segmented by patient demographics into Adults, Pediatric, and Geriatric categories. Adult patients, representing the largest segment, utilize neuromodulation therapies for conditions like chronic pain, depression, and epilepsy. Pediatric patients benefit from neuromodulation in managing epilepsy and certain neurodevelopmental disorders, offering improved quality of life and developmental outcomes. The Geriatric
segment addresses the growing needs of an aging population, focusing on neurodegenerative diseases like Parkinson's and Alzheimer's, as well as chronic pain management. Each demographic group requires tailored approaches to treatment, reflecting the unique medical and therapeutic needs of different age groups. This segmentation highlights the diverse applications of neuromodulation therapies across various stages of life, ensuring targeted and effective patient care.
By Product
Implantable Devices
Deep Brain Stimulators
Spinal Cord Stimulators
Vagus Nerve Stimulators
Intrathecal Drug Delivery Systems
External Devices
Transcranial Magnetic Stimulation (TMS) Devices
Transcranial Direct Current Stimulation (tDCS) Devices
Accessories and Consumables
The Global Neuromodulation is segmented by product into Implantable Devices, External Devices, and Accessories and Consumables. Implantable Devices include Deep Brain Stimulators for Parkinson's, Spinal Cord Stimulators for chronic pain, Vagus Nerve Stimulators for epilepsy and depression, and Intrathecal Drug Delivery Systems for direct spinal medication. External Devices consist of Transcranial Magnetic Stimulation (TMS) Devices for depression and Transcranial
Direct Current Stimulation (tDCS) Devices for brain stimulation. Accessories and Consumables support these devices, ensuring proper operation and maintenance. This segmentation highlights the market's range of invasive and non-invasive products designed to treat various neurological conditions effectively.
By End-User
Hospitals
Neurology Clinics
Ambulatory Surgical Centers
Home Care Settings
The Global Neuromodulation is segmented by end-user into Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Home Care Settings. Hospitals are the primary users, offering comprehensive neuromodulation treatments for various neurological conditions. Neurology Clinics specialize in focused care for disorderslike epilepsy and chronic pain, utilizing advanced neuromodulation techniques. Ambulatory Surgical Centers provide outpatient neuromodulation procedures, ensuring quick recovery and convenience for patients. Home Care Settings cater to patients who require ongoing neuromodulation therapy in a more comfortable and familiar environment. This segmentation highlights the diverse application of neuromodulation technologies across different healthcare settings, ensuring accessible and specialized care for patients.
key Player
Medtronic plc
Boston Scientific Corporation
Nevro Corp
Zynex Inc
ElectroCore, Inc
NeuroMetrix, Inc
Soterix Medical Inc
Bioness Inc
Abbott Laboratories
Helius Medical Technologies, Inc
Blackrock Neurotech
Inspire Medical Systems, Inc
NeuroPace, Inc
Cala Health, Inc
NeuroSigma, Inc
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
Global Cellular Products Market
Global Blue Light Therapy Device Market
Global Artificial Intelligence Based Blood Test Market
Global Digital Pills Market
Global POC Ultrasound Market
Global Needle-Free Blood Testing Market
Global Medical Tourism Market
Gummy Supplements Market
Software As a Medical Device (SaMD) Market
Canada Consumer Healthcare Market
Your phrase has been sent to nick's email. Once he takes action. you will be notified!
Stats And Research ™ Copyright © 2025 .
